HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Salvatore Ulisse Selected Research

Aurora Kinases

11/2017Solid Cancer Treatment With Aurora Kinase Inhibitors: Towards a Personalized Medicine.
10/2016The aurora kinase inhibitor VX-680 shows anti-cancer effects in primary metastatic cells and the SW13 cell line.
5/2016Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line.
1/2015Deregulated expression of Aurora kinases is not a prognostic biomarker in papillary thyroid cancer patients.
10/2014Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines.
1/2014A new aurora in anaplastic thyroid cancer therapy.
9/2011Aurora kinases are expressed in medullary thyroid carcinoma (MTC) and their inhibition suppresses in vitro growth and tumorigenicity of the MTC derived cell line TT.
2/2010Inhibition of the aurora kinases suppresses in vitro NT2-D1 cell growth and tumorigenicity.
6/2008Effects of the Aurora kinase inhibitor VX-680 on anaplastic thyroid cancer-derived cell lines.
7/2006Expression of Aurora kinases in human thyroid carcinoma cell lines and tissues.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Salvatore Ulisse Research Topics

Disease

33Neoplasms (Cancer)
05/2022 - 05/2002
25Thyroid Neoplasms (Thyroid Cancer)
05/2022 - 07/2006
14Anaplastic Thyroid Carcinoma
03/2022 - 06/2008
7Papillary Thyroid Cancer
08/2018 - 02/2011
4Neoplasm Metastasis (Metastasis)
10/2016 - 02/2009
3Breast Neoplasms (Breast Cancer)
01/2022 - 01/2014
3Thyroid Nodule (Nodule, Thyroid)
11/2021 - 05/2017
2Disease Progression
08/2022 - 01/2019
2Autoimmune Thyroiditis (Lymphomatous Thyroiditis)
01/2022 - 02/2012
2Hypothyroidism
07/2019 - 06/2013
2follicular Thyroid cancer
08/2018 - 01/2015
2Renal Cell Carcinoma (Grawitz Tumor)
03/2017 - 12/2013
2Hepatocellular Carcinoma (Hepatoma)
03/2017 - 12/2013
2Lymphatic Metastasis
01/2017 - 02/2013
2medullary Thyroid cancer
11/2016 - 01/2015
2Thyroid Diseases (Thyroid Disease)
06/2016 - 01/2010
2Genomic Instability
05/2016 - 02/2010
2BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/2013 - 03/2011
1Pain (Aches)
08/2022
1Psoriatic Arthritis
08/2022
1Aortic Aneurysm (Aneurysm, Aortic)
08/2022
1Psoriasis (Pustulosis Palmaris et Plantaris)
08/2022
1Obesity
02/2022
1Hypoxia (Hypoxemia)
01/2020
1Goiter
07/2019
1Hypophysitis
05/2019
1Adrenal Insufficiency (Adrenal Gland Hypofunction)
05/2019
1Epidermolysis Bullosa Dystrophica (Dystrophic Epidermolysis Bullosa)
01/2019
1Foot Deformities (Foot Deformity)
01/2019
1Inflammation (Inflammations)
01/2019
1Fibrosis (Cirrhosis)
01/2019
1Congenital Abnormalities (Deformity)
01/2019
1Sarcoma (Soft Tissue Sarcoma)
05/2018
1Diarrhea
11/2016
1Fatigue
11/2016
1Exanthema (Rash)
11/2016

Drug/Important Bio-Agent (IBA)

10Aurora KinasesIBA
11/2017 - 07/2006
7Messenger RNA (mRNA)IBA
01/2018 - 07/2006
6IodineIBA
08/2022 - 01/2015
6Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
03/2022 - 02/2009
6Antineoplastic Agents (Antineoplastics)IBA
12/2021 - 01/2016
5LigandsIBA
03/2019 - 05/2002
4RacivirIBA
04/2022 - 01/2015
4AutoantibodiesIBA
01/2022 - 01/2010
4PlasminogenIBA
11/2021 - 02/2009
4Plasminogen Activators (Plasminogen Activator)IBA
11/2012 - 02/2009
4Proteins (Proteins, Gene)FDA Link
09/2011 - 05/2002
3Monoclonal AntibodiesIBA
08/2022 - 02/2009
3Protein-Tyrosine Kinases (Tyrosine Kinase)IBA
05/2022 - 01/2016
3vandetanib (ZD6474)IBA
05/2018 - 11/2016
3Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
03/2017 - 12/2013
3Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA
03/2017 - 02/2010
3Sorafenib (BAY 43-9006)FDA Link
03/2017 - 12/2013
3Phosphotransferases (Kinase)IBA
01/2016 - 07/2006
3Plasminogen Activator Inhibitor 1IBA
02/2011 - 02/2009
2CytokinesIBA
08/2022 - 01/2018
2Immune Checkpoint InhibitorsIBA
05/2022 - 05/2019
2Plasminogen InactivatorsIBA
03/2022 - 01/2016
2MicroRNAs (MicroRNA)IBA
11/2021 - 01/2020
2lenvatinibIBA
05/2018 - 01/2018
2fms-Like Tyrosine Kinase 3IBA
03/2017 - 12/2013
2Vascular Endothelial Growth Factor Receptors (VEGF Receptors)IBA
03/2017 - 08/2014
2tozasertibIBA
10/2016 - 06/2008
2Biomarkers (Surrogate Marker)IBA
01/2015 - 01/2014
2ThyroglobulinFDA Link
01/2014 - 02/2013
2Imatinib Mesylate (Gleevec)FDA Link
01/2013 - 03/2011
2Urokinase Plasminogen Activator ReceptorsIBA
02/2011 - 04/2010
2Aurora Kinase AIBA
02/2010 - 09/2007
1Pharmaceutical PreparationsIBA
08/2022
1Etanercept (Enbrel)FDA Link
08/2022
1Biosimilar PharmaceuticalsIBA
08/2022
1WX-340IBA
03/2022
1Sirtuin 1IBA
02/2022
1PeroxidasesIBA
12/2021
1AntioxidantsIBA
12/2021
1Transcription Factors (Transcription Factor)IBA
09/2021
1pembrolizumabIBA
05/2019
1avelumabIBA
05/2019
1atezolizumabIBA
05/2019
1IpilimumabIBA
05/2019
1NivolumabIBA
05/2019
1Insulin (Novolin)FDA Link
05/2019
1Gonadal HormonesIBA
05/2019
1Collagen Type VIIIBA
01/2019
1DecorinIBA
01/2019
1Transforming Growth Factors (Transforming Growth Factor)IBA
01/2019
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
05/2018
1Pioglitazone (Actos)FDA Link
01/2018
1Rosiglitazone (Avandia)FDA Link
01/2018
1ChemokinesIBA
01/2018
1CC ChemokinesIBA
01/2018
1ThiazolidinedionesIBA
01/2018
1Peroxisome Proliferator-Activated Receptors (PPAR)IBA
01/2018
1CCR2 ReceptorsIBA
01/2018

Therapy/Procedure

11Therapeutics
08/2022 - 02/2009
3Drug Therapy (Chemotherapy)
04/2022 - 01/2012
3Immunotherapy
01/2022 - 03/2019
2Thyroidectomy
05/2017 - 04/2009
2Radiotherapy
01/2013 - 01/2012
1Precision Medicine
11/2017